These findings, together with prior work showing PSGL-1 functioned as a negative regulator in T cells (43), suggest that inhibiting PSGL-1 in CD4+ T cells through multiple immunotherapeutic strategies may represent a new strategy to improve anti-tumor immunity. The gene discussed is CD4; the disease is neoplasm.